NCT05180994RecruitingPhase 1/2
Topical Infliximab in Eyes With Penetrating Keratoplasty
Source: ClinicalTrials.gov · Last updated 27 Apr 2026
Brief summary (registry, in English)
Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 29 Nov 2021
- Start date
- 1 May 2022
- Primary completion date
- 1 Mar 2027
- Lead sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
- Diseases
- Glaucoma
- NCT number
- NCT05180994
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 50
- From 1 May 2022 to the primary completion date, 1 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Past corneal transplant (any technique);
- Current or anterior use of anti-TNF-α medication or other anti-inflammatory biologics.
Other illness
- Active ocular infection;
- Advanced glaucoma or macular disease;
- Active or latent systemic infection (tuberculosis, histoplasmosis, coccidioidomycosis, cytomegalovirus, pneumocystis, aspergillosis or hepatitis B);
- Malignancy diagnosed in the past 5 years (any kind);
- Demyelinating disease;
- History or current diabetes mellitus (controlled or uncontrolled) or heart failure (New York Heart Association class III or IV);
- Allergy to infliximab or to a compound of its topical formulation;
Lab values
- Significant anomaly of complete blood count or hepatic enzymes;
Other
- Pregnancy or breastfeeding;
Who the study is looking for
- Age between 18 and 80 years;
- First corneal transplant surgery;
- Capable of providing informed consent;
- Capable of administering eye medication or access to a caregiver able and willing to administer the eye medication for the patient.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier de l'Université de Montréal Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.